{"id":"W3216382063","doi":"10.1182/blood-2021-153897","title":"Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Fleurimont; University Health Network; Moncton Hospital; CancerCare Manitoba","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Oncology; Dexamethasone; Proteasome inhibitor; Minimal residual disease; Cyclophosphamide; Immunology; Melphalan; Internal medicine; Population; Cancer research; Chemotherapy; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001587342,0.001095818,0.002598387,0.0003500906,0.0004863205,0.001589663,0.0006824135,0.001223733,0.003627006],"category_scores_gemma":[0.0009001456,0.0005105992,0.002466298,0.0004347882,0.0008398867,0.0009701562,0.0003879784,0.002927176,0.000696018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009612522,"about_ca_system_score_gemma":0.001175425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000616259,"about_ca_topic_score_gemma":0.001278848,"domain_scores_codex":[0.9994511,0.0002326898,0.00004228512,0.0001229254,0.00005938041,0.00009165287],"domain_scores_gemma":[0.999168,0.0001535276,0.0001830834,0.00007358989,0.00007925187,0.0003425544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7350796,0.1299906,0.007849306,0.002664183,0.004551823,0.0003461516,0.000308234,0.001388125,0.02947341,0.0002135315,0.002129624,0.0860054],"study_design_scores_gemma":[0.3976883,0.5770455,0.01721718,0.0001519819,0.001657157,0.0003371095,0.0001047171,0.0006897019,0.001894254,0.0001474136,0.00302392,0.00004273181],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882014,0.007258305,0.0004845462,0.0004121532,0.0002074944,0.001980043,0.0006272766,0.00003965372,0.0007891806],"genre_scores_gemma":[0.9876111,0.004943009,0.001129861,0.001016782,0.0003324349,0.00213387,0.001204142,0.00001611161,0.001612575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003627006,"threshold_uncertainty_score":0.01213354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03596997471734512,"score_gpt":0.3413762792306013,"score_spread":0.3054063045132561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}